| アブストラクト | BACKGROUND/AIM: Chemotherapy-induced peripheral neuropathy (CIPN) due to oxaliplatin (L-OHP) is a major clinical problem. Effective and safe preventive strategies for CIPN are urgently needed. Although proton pump inhibitors (PPIs) have various off-target effects, their clinical impact on L-OHP-induced CIPN remains unclear. In the present study, we investigated the effects of PPIs on L-OHP-induced CIPN in patients using two real-world clinical databases. PATIENTS AND METHODS: We retrospectively analyzed the electronic medical records of Osaka University Hospital to examine the effect of PPIs on CIPN development in 217 patients who received XELOX (L-OHP plus capecitabine) therapy for colorectal cancer. In addition, the Japanese Adverse Drug Event Report (JADER) database was used to validate the effects of PPIs on L-OHP-induced CIPN. RESULTS: The incidences of CIPN (grade >/=2) and discontinuation of L-OHP were significantly lower in patients with PPIs than in those without PPIs. Multivariate analysis showed that concomitant PPIs use was an independent factor that significantly contributed to the prevention of grade >/=2 CIPN (odds ratio=0.054, p<0.001). Kaplan-Meier analysis showed that the time to onset of grade >/=2 CIPN was significantly prolonged in patients with PPIs without affecting the therapeutic efficacy of L-OHP (p=0.004). Moreover, JADER database analyses revealed that the reporting odds ratio of any PPI for L-OHP-induced CIPN was 0.485. CONCLUSION: Concomitant PPI use ameliorated L-OHP-induced CIPN in patients with colorectal cancer. |
|---|
| 組織名 | Department of Hospital Pharmacy, Graduate School of Medicine, Osaka University,;Suita, Japan.;Department of Pharmacy, Osaka University Hospital, Suita, Japan.;Suita, Japan; ikemurak@hp-drug.med.osaka-u.ac.jp.;Department of Molecular Pharmaceutical Science, Graduate School of Medicine,;Osaka University, Suita, Japan.;Division of Glocal Pharmacology, Department of Pharmacology, Graduate School of;Medicine, Osaka University, Suita, Japan.;Department of Hospital Pharmacy, School of Pharmaceutical Sciences, Osaka;University, Suita, Japan. |
|---|
